Bryn Pharma is focused on developing an innovative, needle-free epinephrine nasal spray designed to provide a more accessible and user-friendly alternative for individuals at risk of anaphylaxis. The company aims to address significant gaps in current treatment options, particularly the challenges posed by traditional autoinjectors, which many patients find cumbersome or intimidating due to their needle-based delivery. The proposed nasal spray, referred to as NDS1C, is designed to be portable, easy to use, and affordable, allowing patients to carry it conveniently and administer it without the need for medical training. 

Clinical studies conducted by Bryn Pharma have shown that the pharmacokinetic (PK) profile of NDS1C is comparable to that of the standard 0.3 mg intramuscular autoinjector, with a more rapid absorption rate during critical moments of anaphylactic events. The nasal spray has demonstrated safety across various studies, with no serious adverse events reported. Additionally, preference studies indicate that both healthcare professionals and patients favor the bi-dose intranasal epinephrine spray over traditional autoinjectors, citing factors such as comfort, ease of use, and portability. This innovative approach represents a significant advancement in the management of anaphylaxis, potentially improving treatment outcomes for those affected.

United States

Bryn Pharma is a privately held pharmaceutical company based in North Carolina.  Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis.  

The mission of Bryn Pharma is to empower patients with a life-saving device that is small enough to comfortably fit in your pocket and easy to use in the event of an anaphylactic attack.

Our intranasal delivery system will be an exciting alternative to epinephrine auto-injectors providing patients a needle-free option that is easy to use, portable, and affordable.



Bryn Pharma

Company Details